Prolia Mechanism of Action*

Prolia is the first RANK ligand inhibitor. Prolia’s mechanism of action inhibits the activity of osteoclasts before they get to bone; decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone throughout the skeleton.1*

learn more

Down arrow

Mechanism of Action in Postmenopausal Osteoporosis*

Adapted from the respective Product Monographs.1,2
*Clinical significance has not been established.
† Comparative clinical significance has not been established.
Additional Resources
Amgen Canada Icon
Amgen Canada

Learn more about Amgen Canada

Amgen canada
websiteArrow Image
References
1. Amgen Canada Inc. Prolia® (denosumab injection) Product Monograph. November 24, 2023.
2. Allergan Inc. Actonel®/Actonel DR® Product Monograph. November 3, 2022.
Safety logo

You are now leaving the Prolia.ca website.

The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on the linked sites. Such links do not imply Amgen's endorsement of material on any other site, and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to such linked sites is at your own risk.

Do you want to link to our other external sites and leave Prolia.ca?

You are now leaving the Prolia.ca website. Please note that the information you are about to view may not comply with Canadian regulatory requirements. Marketing authorizations and availability of products may differ between Canada and other countries.

Proceed

Do you want to link to another Amgen Canada site?

Yes, leave Prolia.ca  

You are now leaving the Prolia.ca website. Please note that these links are being provided as a convenience and for informational purposes only.